Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


3 Blood
1 Bone Marrow Transplant
1 Br J Haematol
1 Cancer
1 Eur J Haematol
1 Int J Cancer
2 Int J Radiat Oncol Biol Phys
1 Leuk Lymphoma
1 Leukemia

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles


  1. HERBAUX C, Merryman R, Devine S, Armand P, et al
    Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.
    Blood. 2018 May 2. pii: blood-2018-02-811174. doi: 10.1182/blood-2018-02-811174.
    PubMed     Text format     Abstract available

  2. CERIANI L, Milan L, Martelli M, Ferreri AJM, et al
    Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
    Blood. 2018 May 2. pii: blood-2018-01-826958. doi: 10.1182/blood-2018-01-826958.
    PubMed     Text format     Abstract available

  3. LACASCE AS, Bociek RG, Sawas A, Caimi P, et al
    Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    Blood. 2018 Apr 27. pii: blood-2017-11-815183. doi: 10.1182/blood-2017-11-815183
    PubMed     Text format     Abstract available

    Bone Marrow Transplant

  4. YANG L, Tan Y, Shi J, Zhao Y, et al
    Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.
    Bone Marrow Transplant. 2018 Apr 30. pii: 10.1038/s41409-018-0184.
    PubMed     Text format    

    Br J Haematol

  5. PARSONS SK, Kelly MJ, Cohen JT, Castellino SM, et al
    Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.
    Br J Haematol. 2018 Apr 29. doi: 10.1111/bjh.15255.
    PubMed     Text format     Abstract available


  6. ROMAGUERA JE, Wang M, Feng L, Fayad LE, et al
    Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
    Cancer. 2018 May 3. doi: 10.1002/cncr.31361.
    PubMed     Text format     Abstract available

    Eur J Haematol

  7. GOLSTEIN S, Muylle K, Vercruyssen M, Spilleboudt C, et al
    Long-term follow-up of 2 patients treated with (90) Y-rituximab Radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphoma.
    Eur J Haematol. 2018 May 2. doi: 10.1111/ejh.13087.
    PubMed     Text format     Abstract available

    Int J Cancer

  8. BANDAPALLI OR, Paramasivam N, Giangiobbe S, Kumar A, et al
    Whole genome sequencing reveals DICER1 as a candidate predisposing gene in familial Hodgkin lymphoma.
    Int J Cancer. 2018 Apr 30. doi: 10.1002/ijc.31576.
    PubMed     Text format    

    Int J Radiat Oncol Biol Phys

  9. PARZUCHOWSKI A, Bush R, Pei Q, Friedman DL, et al
    Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031.
    Int J Radiat Oncol Biol Phys. 2018;100:1119-1125.
    PubMed     Text format     Abstract available

  10. CONSTINE LS, Yahalom J, Ng AK, Hodgson DC, et al
    The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.
    Int J Radiat Oncol Biol Phys. 2018;100:1100-1118.
    PubMed     Text format     Abstract available

    Leuk Lymphoma

  11. SPINA F, Radice T, De Philippis C, Soldarini M, et al
    Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
    Leuk Lymphoma. 2018 May 1:1-9. doi: 10.1080/10428194.2018.1459607.
    PubMed     Text format     Abstract available


  12. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.